- Home
- HUDI vs BCAB Comparison
HUDI vs BCAB Comparison
Compare HUDI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUDI
- BCAB
- Stock Information
- Founded
- HUDI 2018
- BCAB 2007
- Country
- HUDI China
- BCAB United States
- Employees
- HUDI N/A
- BCAB N/A
- Industry
- HUDI Steel/Iron Ore
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- HUDI Industrials
- BCAB Health Care
- Exchange
- HUDI Nasdaq
- BCAB Nasdaq
- Market Cap
- HUDI 23.1M
- BCAB 27.0M
- IPO Year
- HUDI 2021
- BCAB 2020
- Fundamental
- Price
- HUDI $1.57
- BCAB $0.41
- Analyst Decision
- HUDI
- BCAB Buy
- Analyst Count
- HUDI 0
- BCAB 2
- Target Price
- HUDI N/A
- BCAB $5.00
- AVG Volume (30 Days)
- HUDI 32.0K
- BCAB 834.0K
- Earning Date
- HUDI 02-28-2025
- BCAB 03-25-2025
- Dividend Yield
- HUDI N/A
- BCAB N/A
- EPS Growth
- HUDI N/A
- BCAB N/A
- EPS
- HUDI 0.01
- BCAB N/A
- Revenue
- HUDI $74,270,429.00
- BCAB $11,000,000.00
- Revenue This Year
- HUDI N/A
- BCAB N/A
- Revenue Next Year
- HUDI N/A
- BCAB N/A
- P/E Ratio
- HUDI $163.02
- BCAB N/A
- Revenue Growth
- HUDI N/A
- BCAB N/A
- 52 Week Low
- HUDI $1.47
- BCAB $0.38
- 52 Week High
- HUDI $3.45
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- HUDI 43.70
- BCAB 32.49
- Support Level
- HUDI $1.56
- BCAB $0.42
- Resistance Level
- HUDI $1.74
- BCAB $0.50
- Average True Range (ATR)
- HUDI 0.10
- BCAB 0.05
- MACD
- HUDI 0.01
- BCAB 0.02
- Stochastic Oscillator
- HUDI 30.93
- BCAB 20.97
About HUDI Huadi International Group Co. Ltd.
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.